<DOC>
	<DOCNO>NCT01089231</DOCNO>
	<brief_summary>The aim study investigate effect short- long-term intervention EPA DHA-rich fish oil gene expression profile healthy hyperlipidemic male .</brief_summary>
	<brief_title>Effects Omega-3 Fatty Acids Human Gene Expression</brief_title>
	<detailed_description>Cardiovascular coronary heart disease continue lead cause morbidity mortality among adult Europe North America . Since number elderly people therefore number chronic-inflammatory disease rise , preventive therapy become important . Within preventive strategy , nutrition play central role . Cross-sectional study suggest omega-3 fatty acid , especially long-chain fatty acid Eicosapentaenoic acid ( EPA , C20:5ω3 ) Docosahexaenoic acid ( DHA , C22:6ω3 ) , protective cardiovascular coronary heart disease . Their cardio protective potential base positive effect blood lipid , vascular tonus blood clotting . A number control clinical trial show EPA DHA supplementation lower fast postprandial plasma concentration triglyceride-rich lipoprotein remnant . Biochemical research reveal numerous metabolic effect EPA DHA , range effect membrane fluidity modification eicosanoid profile . However , human clinical trial examine regulative effect DHA EPA supplementation gene expression . Furthermore , knowledge publish research data available deal effect fatty acid gene expression subject hypertriglyceridemia comparison healthy subject . Such finding great concern due hint especially people hypertriglyceridemia benefit triglyceride lower effect EPA DHA supplementation . Presently well-established gene regulative potential EPA DHA person differs healthy person . These finding could help understand difference metabolic effect EPA DHA healthy vs. hypertriglyceridemic person , great risk cardiovascular coronary disease . Finally , data could contribute knowledge basis target strategy preventive therapy long-chain omega-3 fatty acid EPA DHA .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>male , 2050 year nonsmokers ethnicity : Caucasians medical treatment healthy subject : document disease normal blood lipid ( triglyceride &lt; 150 mg/dl ; total cholesterol &lt; 200 mg/dl ) human increase blood lipid ( hyperlipidemia ) document hypertriglyceridemia triglyceride ≥ 150 mg/dl ( ≥ 1,7 mmol/l ) total cholesterol &gt; 200 mg/dl ( 5,2 mmol/l ) write confirmation subject detailed oral write explanation study content , requirement risk ability willingness participant attend investigator 's order ( compliance study condition , consumption study medicament accord dosage commendation ) BodyMassIndex ( BMI ) ≥ 35 smoker medical treatment ( especially corticosteroid , antiinflammatory drug , blood lipid lower drug ( e.g . statin , fibrates , bile acid exchanger resin , phytosterols ) take supplement omega3 fatty acid , phytosterols , polyglucosamines ( Chitosan ) lipid bind ingredient daily consumption omega3 fatty acid rich fish ( salmon , mackerel , herring ) heavy chronic disease ( tumor , diabetes typ 1 , etc . ) , documented heart disease , document blood clotting disorder , renal failure , liver disease document blood clot disorder consumption coagulationinhibiting drug ( example Marcumar , ASS ) allergy intolerance fish/fish oil study ingredient test product chronic gastrointestinal disease ( Colitis ulcerosa , Morbus Crohn , pancreatic insufficiency ) donation blood last 6 week routine consumption laxative common exclusion criterion like alcohol , drug and/or medicament dependence subject agreement study condition refusal rather reset consent subject active participation investigational drug device trial within last 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>gene expression</keyword>
	<keyword>fish oil</keyword>
	<keyword>DHA , EPA</keyword>
</DOC>